NoVel Trimeric Maleimide Cross-Linking Reagents
assemble peptide-peptoid structures.8 Trimesic acid was used
in the construction of aromatic tripodal systems as model
receptors for monosaccharides and other compounds.9 Also,
triamines derived from cyclohexane tricarboxylic acids 1 and
2 are used as chelating agents of trivalent cations.10
FIGURE 1. Structure of C3-symmetric templates.
The preparation of the scaffolds according to our model
requires the attachment of the spacers to the templates and the
incorporation of a maleimide moiety. Maleimide-containing
compounds have been widely employed as intermolecular cross-
linking agents in chemical and biochemical applications for
chemoselective ligation to cysteine-containing peptides and
proteins.11 It was reported that homobifunctional cross-linking
reagents can be used as molecular rulers to evaluate the distance
between two cross-linked amino acid residues; the quantitative
measure of the lengths has been estimated by stochastic dynamic
calculations.12
constrained to be 3-fold symmetric. The binding of CD4/gp120
takes place predominantly via electrostatic interactions within
a large and irregular interface. A protuberant Phe43 of CD4
inserts into a receptive hole of gp120, the “Phe-43 cavity”, which
is the conserved CD4 binding site on gp120.4 Compounds that
interfere with the binding of CD4-gp120 are therefore inhibitors
of HIV entry. Additionally, a trimeric structure bearing C-
peptide sequences of the gp41 ectodomain could also mimic
the prehairpin intermediate and therefore provide a tool to block
the fusion event. It has also been reported that a multivalent
assembly of gp41 peptides enhances the R-helix content of the
peptide and provides a model to mimic the HIV membrane
fusion state.5
In this paper we present the synthesis, conformational
behavior, and flexibility of trimeric maleimide clusters, com-
pounds 4a-6c,13 as homotrifunctional cross-linking reagents
(Figure 2). Since these derivatives are large molecules that can
adopt different conformations in solution, the study could
provide useful information regarding the molecular shape of
CD4 cellular receptors as well as the prehairpin intermediate
involved in the HIV-cell fusion event.
We have recently reported a series of trivalent CD4-mimetic
miniproteins designed to match the distance between any two
of the CD4 binding cavities by having three CD4M9 moieties
tethered through a spacer to a 3-fold symmetric template.6 They
have shown significantly enhanced activity over the monovalent
CD4M9 but activites similar to those of the bivalent system
first reported by Wang and co-workers.7 In this work, we report
the synthesis of several new C3 symmetric templates that could
serve as scaffolds to which CD4 mimetic peptides or minipro-
teins can be attached. Conformational analysis was used to
characterize the different rigidities, flexibilities, and spatial
orientations of each system to better understand their molecular
behavior.
Results and Discussions
Synthesis and NMR Study. The preparation of N-substituted
maleimide derivatives is not an easy task. Several procedures
have been described that involve the formation of the maleimide
moiety by ring closure of the intermediate amide, obtained by
reaction of amines with maleic anhydride14 or through a retro-
Diels-Alder reaction of the adduct generated between furan
and maleimide.15 These methods require refluxing at high
temperatures, and in the first case, low yields are obtained
because of the low solubility of the maleic acid derivatives.
Direct N-alkylation of maleimide under Mitsunobu conditions
has also been used to introduce this functionality. However,
For the preparation of our scaffolds we have chosen C3-
symmetric templates of well-defined architectures such as
cis,cis-1,3,5-trimethyl cyclohexane tricarboxylic acid (Kemp’s
triacid, 1), cis,cis-cyclohexane-1,3,5-tricarboxylic acid (2), and
trimesic acid (3) (Figure 1) that are joined to synthetic or
commercial spacers of different lengths. Kemp’s triacid is known
in supramolecular chemistry as a useful building block to
(8) (a) Jefferson, E. A.; Locardi, E.; Goodman, M. J. Am. Chem. Soc.
1998, 129, 7420-7428. (b) Feng, Y.; Melacini, G.; Taulane, J. P.; Goodman,
M. J. Am. Chem. Soc. 1996, 118, 10351-10358. (c) Kocis, P.; Issakova,
O.; Sepetov, N. F.; Lebl, M. Tetrahedron Lett. 1995, 36, 6623-6626.
(9) (a) Vacca, A.; Nativi, C.; Cacciarini, M.; Pergoli, R.; Roelens, S. J.
Am. Chem. Soc. 2004, 126, 16456-16465. (b) Gibson, S. E.; Castaldi, M.
P. Chem. Commun. 2006, 3045-3062.
(2) (a) Gallo, S. A.; Puri, A.; Blumenthal, R. Biochemistry 2001, 40,
12231-12236. (b) Melikyan, G. B.; Markosyan, R. M.; Hemmati, H.;
Delmedico, M. K.; Lambert, D. M.; Cohen, F. S. J. Cell Biol. 2000, 151,
413-424. (c) Mun˜oz-Barroso, I.; Durell, S.; Sakaguchi, K.; Appella, E.;
Blumenthal, R. J. Cell Biol. 1998, 140, 315-323. (d) LaBranche, C. C.;
Galasso, G.; Moore, J. P.; Bolognesi, D. P.; Hirsch, M. S.; Hammer, S. M.
AntiViral Res. 2001, 50, 95-115.
(3) (a) Kwong, P. D.; Wyatt, R.; Robinson, J.; Sweet, R. W.; Sodroski,
J.; Hendrickson, W. A. Nature 1998, 393, 648-659. (b) Wyatt, R.; Kwong,
P. D.; Desjardins, E.; Sweet, R. G.; Robinson, J.; Hendrickson, W. A.;
Sodroski, J. G. Nature 1998, 393, 705-711.
(4) (a) Hsu, S.-T. D.; Bonvin, A. M. J. Proteins: Struct., Funct., Bioinf.
2004, 55, 582-593. (b) Kwong, P. D.; Wyatt, R.; Majeed, S.; Robinson,
J.; Sweet, R. W.; Sodroski, J.; Hendrickson, W. A. Structure 2000, 8, 1329-
1339. (c) Kwong, P. D.; Wyatt, R.; Hendrickson, W. A. J. Virol. 2000,
1961-1972.
(10) Bowen, T.; Planalp, R. P.; Brechbiel, M. W. Bioorg. Med. Chem.
Lett. 1996, 6, 807-810.
(11) (a) Hermanson, G. T. In Bioconjugate Techniques; Academic
Press: New York, 1996, p 148. (b) Shin, I.; Jung, H.-J.; Lee, M.-R.
Tetrahedron Lett. 2001, 42, 1325-1328. (c) Peters, K.; Richards, F. M.
Annu. ReV. Biochem. 1977, 46, 523-551. (d) Zecherle, G. N.; Oleinikov,
A.; Traut, R. R. J. Biol. Chem. 1992, 267, 5889-5894. (e) Kwaw, J. S.;
Kaback, H. R. Biochemistry 2000, 39, 3134-3140. (f) Swaney, J. B.
Methods Enzymol. 1986, 128, 613-626. (g) Holmes, K. C.; Popp, D.;
Gebhard, W.; Kabsch, W. Nature 1990, 347, 44-49. (h) Lorenz, M.; Popp,
D.; Holmes, K. C. J. Mol. Biol. 1993, 234, 826-836.
(12) Green, N.; Reisler, E.; Houk, K. N. Protein Sci. 2001, 10, 1293-
1304.
(13) The synthesis and chemical characterization of compounds 4a-c
and 5c is reported in ref 6.
(5) (a) Ni, J.; Powell, R.; Baskakov, I. V.; DeVico, A.; Lewis, G. K.;
Wang, L.-X. Bioorg. Med. Chem. 2004, 12, 3141-3148. (b) Tam, J. P.;
Yu, Q. Org. Lett. 2002, 4, 4167-4170. (c) Gochin, M.; Kiplin Guy, R.;
Case, M. A. Angew. Chem. Int. Ed. 2003, 42, 5325-5328.
(6) Li, H.; Song, H.; Guan, Y.; Szczepanska, A.; Moreno-Vargas, A. J.;
Carmona, A. T.; Robina, I.; Lewis, G. K.; Wang, L.-X. Bioorg. Med. Chem.
2007, 15, 4220-4228.
(14) Reddy, P.; Y.; Kondo, S.; Fujita, S.; Toru, T. Synthesis 1998, 999-
1002.
(15) Farha, O. K.; Julios, R. L.; Hawthorne, M. F. Tetrahedron Lett.
2006, 47, 2619-2622.
(7) Li, H.; Song, H.; Heredia, A.; Le, N.; Redfield, R.; Lewis, G. K.;
Wang, L.-X. Bioconjugate Chem. 2004, 15, 783-789.
J. Org. Chem, Vol. 72, No. 18, 2007 6777